CBRS heads into the week of June 16 carrying an uncomfortable split: options traders are growing more optimistic, the lending market has never been tighter, and the stock is down 24% over the past month.
The most striking development in the lending market is that borrow availability has hit zero. Every share in the lending pool is currently lent out — the tightest reading since listing and a full collapse from the 128% availability level recorded just three weeks ago on May 27. That rapid exhaustion of supply happened alongside a sustained build in short interest: shares short have climbed to roughly 9.6 million, holding near five times the 1.9 million level that persisted through most of May. Despite the zero availability, cost to borrow has fallen sharply — down 31% on the week to just 0.79% — which reflects a borrow market where new shorts simply cannot find shares rather than one where existing borrowers are being squeezed on rate. The ORTEX short score has stabilised in the high 60s, consistent with elevated but not extreme bearish positioning.
Options are sending a different message. Call demand has been building steadily since late May, and the put/call ratio has dropped to 0.52 — nearly 1.7 standard deviations below its 20-day average of 0.72. That is the most call-skewed reading in the trailing history. Put another way, the hedging that dominated through May and into the June 12 earnings print has largely unwound, replaced by more directionally bullish positioning. This divergence between options sentiment and short interest is the central tension on the tape right now: one group is leaning into the stock, the other is standing firm against it.
The Street is firmly in the bulls' camp. Ten firms launched coverage in the week of June 8 — Morgan Stanley, Mizuho, UBS, Citigroup, Barclays, TD Cowen, Needham, Rosenblatt, Wedbush, and Craig-Hallum — every one at Buy, Outperform, or Overweight. Targets range from $250 to $340, with a consensus mean near $293 against a current price of $212.25, implying roughly 38% upside on analyst numbers. The bull case rests on Cerebras's wafer-scale architecture, OpenAI and AWS partnerships, and a projected revenue inflection through 2026-27. Bears counter with customer concentration — OpenAI is expected to drive the majority of revenue through 2028 — early-stage profitability, and the risk that better-capitalised chip makers crowd the inference market. Valuation offers little comfort to either side: the company is loss-making, the EV/EBITDA multiple has compressed to 32.7x from higher levels earlier in the month, and the price-to-book ratio of 12x reflects a market still pricing in a premium growth trajectory despite the recent sell-off.
Insider activity adds one more layer of complexity. In mid-May, four executives — including CEO Andrew Feldman and COO Dhiraj Mallick — sold a combined $132 million worth of stock at $185 per share. Mallick's sale alone totalled $91 million, making it the largest individual transaction. Those sales came with the stock below current levels, and the trade significance scores were low, suggesting pre-arranged plans. Still, the net insider flow over the past 90 days is a material outflow, and with the stock now trading at $212 — above the May sale price — it is worth monitoring whether further selling emerges at elevated levels.
The next scheduled catalyst is earnings on August 28. Between now and then, the data points to watch are whether borrow availability remains at zero or begins to loosen as shares return to the lending pool, and whether the put/call ratio continues its descent toward the 52-week low or reverses as traders reassess the post-earnings landscape.
See the live data behind this article on ORTEX.
Open CBRS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
